https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19245
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADCarbamazepine may induce CYP 3A4 and P-gp and decrease the plasma concentration of Glecaprevir / Pibrentasvir.
Possible decrease of clinical efficacy.
–
–
–
Avoid association.
See comments.
Gabapentin, pregabalin, levetiracetam, brivaracetam, or valproic acid
–
–
Reference number |
---|
# patients |
HCV |
Dose |
Frequency |
AUC |
Cmax |
3373 |
---|
10 |
- |
300/120 mg |
x 1 |
- 66%/- 51% |
- 67%/- 50% |
3373 |
---|
10 |
- |
200 mg |
BID |
Ref #3373 : No significant changes in carbamazepine concentrations.
Ref #3524 : Case report of five patients who received standard doses for the treatment of chronic hepatitis C infection while being maintained on first generation anticonvulsants (carbamazepine, phenobarbital, phenytoin). Four patients were treated with glecaprevir/pibrentasvir for 8 weeks and one patient with ledipasvir/sofosbuvir for 12 weeks. All five patients achieved a sustained virologic response (SVR) despite this drug interaction. The authors conclude that all efforts to prevent concomitant use with strong inducers should be made.